Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A.
| Autor: | Alusi G; Barts Health NHS Trust, LondonE1 2ES, U.K., Berry-Kravis E; Department of Pediatrics, Neurological Sciences, and Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois60612, United States., Nelson D; Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas77030, United States., Orefice LL; Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts02114, United States.; Department of Genetics, Harvard Medical School, Boston, Massachusetts02115, United States., Booker SA; Simons Initiative for the Developing Brain, University of Edinburgh, EdinburghEH8 9XD, U.K. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ACS chemical neuroscience [ACS Chem Neurosci] 2022 Dec 21; Vol. 13 (24), pp. 3544-3546. Date of Electronic Publication: 2022 Dec 07. |
| DOI: | 10.1021/acschemneuro.2c00674 |
| Abstrakt: | Understanding how best to treat aspects of Fragile X syndrome has the potential to improve the quality of life of affected individuals. Such an effective therapy has, as yet, remained elusive. In this article, we ask those researching or affected by Fragile X syndrome their views on the current state of research and from where they feel the most likely therapy may emerge. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|